Open AccessEXPRESSION OF CD10 IN CARCINOMA PROSTATE AND ITS CORRELATION WITH VARIOUS CLINICOPATHOLOGICAL PARAMETERS.
Author(s) -
Raj K. Gupta,
Namita Bhutani,
Sunil Arora
Publication year - 2020
Publication title -
international journal of scientific research
Language(s) - English
DOI - 10.36106/ijsr/4631984
Subject(s) - medicine , immunohistochemistry , prostate cancer , lymph node , pathology , immunostaining , prostate , oncology , cancer , carcinoma , adenocarcinoma
Aim: Adenocarcinoma of the prostate is the second most common cause of cancer. Loss of CD10 is a common early event in human prostate cancer and is seen in lower Gleason Score malignancies while increased and altered expression is seen in high Gleason Score tumors, lymph node and bone metastasis. Materials and methods: The present study was a prospective observational study conducted on seventy-five patients suspected of having prostate cancer. Immunohistochemical profile was assessed for PSA, AMACR and CD10 immunostain. The intensity of CD10 expression and pattern of CD10 staining of tumor cells was evaluated.Results: The patients were in age group of 50-90 years with a mean age of 70.97 ± 9.51 years. As the grade group/gleason score increased the number of cases showing negative expression decreased and the pattern of expression changed from membranous to cytoplasmic to both types of expression. As the serum PSA levels increased the intensity of expression changed from focally positive to diffusely positive. The pattern of expression also changed from membranous to cytoplasmic to both ( membranous + cytoplasmic ) types of expression with increase in PSA levels.Conclusion: By immunohistochemical analysis we can identify CD10 positive tumors, which may warrant more aggressive initial therapy. A number of drugs against CD10 are available based on which potential targeted therapies could be formulated.